[1]何才剑,万全增,陈天鹏,等.益气温经方在绝经后骨质疏松症肾虚血瘀证治疗中的应用[J].中医正骨,2021,33(08):7-11.
　HE Caijian,WAN Quanzeng,CHEN Tianpeng,et al.Application of Yiqi Wenjing Fang(益气温经方)in treatment of kidney-deficiency-blood-stasis-type postmenopausal osteoporosis:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(08):7-11.
点击复制

益气温经方在绝经后骨质疏松症肾虚血瘀证治疗中的应用()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第33卷
期数:
2021年08期
页码:
7-11
栏目:
临床研究
出版日期:
2021-08-20

文章信息/Info

Title:
Application of Yiqi Wenjing Fang(益气温经方)in treatment of kidney-deficiency-blood-stasis-type postmenopausal osteoporosis:a clinical study
作者:
何才剑1; 万全增2; 陈天鹏1; 周航1; 房谋昊1; 余阳1; 唐彬彬3; 史晓林3
(1.浙江中医药大学第二临床医学院,浙江 杭州 310053; 2.济宁市中医院,山东 济宁 272003; 3.浙江中医药大学附属第二医院,浙江 杭州 310005)
Author(s):
HE Caijian1; WAN Quanzeng2; CHEN Tianpeng1; ZHOU Hang1; FANG Mouhao1; YU Yang1; TANG Binbin3; SHI Xiaolin3
1.The Second Clinical Medical College of Zhejiang Chinese Medical University,Hangzhou 310053,Zhejiang,China2.Jining Hospital of Traditional Chinese Medicine,Jining 272003,Shandong,China3.The Second Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310005,Zhejiang,China
关键词:
骨质疏松; 绝经后;  肾虚血瘀;  骨密度;  益气温经方;  碳酸钙;  阿法骨化醇;  临床试验
Keywords:
osteoporosis; postmenopausal;  kidney deficiency and blood stagnation;  bone density;  Yiqi Wenjing Fang;  calcium carbonate;  alfacalcidol;  clinical trial
摘要:
目的:观察益气温经方在绝经后骨质疏松症(postmenopausal osteoporosis,PMOP)肾虚血瘀证治疗中的应用价值。方法:将符合要求的240例PMOP肾虚血瘀证患者随机分为2组,每组120例,分别采用口服益气温经方联合碳酸钙D3片和阿法骨化醇胶囊(益气温经方组)与单纯口服碳酸钙D3片和阿法骨化醇胶囊(基础用药组)治疗。益气温经方,每日2次,每次1袋,每袋200 mL; 碳酸钙D3片,每日1次,每次1片; 阿法骨化醇胶囊,每日1次,每次1粒; 均3个月为1个疗程,疗程间隔1个月,共9个疗程。分别于治疗结束时、治疗结束后2年比较2组患者再骨折情况,分别于治疗前及治疗结束时、治疗结束后2年比较2组患者腰椎骨密度、腰背部疼痛视觉模拟量表(visual analogue scale,VAS)评分,并观察并发症发生情况。结果:①受试者退出情况。共20例患者退出试验,益气温经方组13例因腹泻及不愿再服中药退出,基础用药组7例因服用其他药物退出。②再骨折发生情况。治疗结束时,益气温经方组4例出现再骨折、基础用药组6例出现再骨折; 2组患者再骨折发生率比较,差异无统计学意义(χ2=0.313,P=0.576)。治疗结束后2年,益气温经方组6例出现再骨折、基础用药组16例出现再骨折; 益气温经方组再骨折发生率低于基础用药组(χ2=4.466,P=0.035)。③腰椎骨密度。时间因素和分组因素存在交互效应(F=3.063,P=0.048); 2组患者腰椎骨密度总体比较,组间差异有统计学意义,即存在分组效应(F=11.788,P=0.000); 治疗前后不同时间点腰椎骨密度的差异有统计学意义,即存在时间效应(F=4.299,P=0.014); 益气温经方组患者腰椎骨密度治疗前后比较,差异无统计学意义[(54.902±32.465)mg·cm-3,(58.174±14.320)mg·cm-3,(54.223±14.053)mg·cm-3,F=0.943,P=0.391]; 基础用药组患者腰椎骨密度随时间变化呈下降趋势[(55.449±32.111)mg·cm-3,(50.800±20.377)mg·cm-3,(44.283±10.340)mg·cm-3,F=6.242,P=0.002]; 治疗前,2组患者腰椎骨密度比较,差异无统计学意义(t=0.126,P=0.900); 治疗结束时、治疗结束后2年,益气温经方组患者腰椎骨密度均高于基础用药组(t=3.708,P=0.002; t=5.998,P=0.000)。④腰背部疼痛VAS评分。时间因素和分组因素不存在交互效应(F=0.799,P=0.460); 2组患者腰背部疼痛VAS评分总体比较,组间差异无统计学意义,即不存在分组效应(F=3.920,P=0.271); 治疗前后不同时间点腰背部疼痛VAS评分的差异有统计学意义,即存在时间效应(F=402.283,P=0.000); 2组患者腰背部疼痛VAS评分随时间变化均呈下降趋势,且2组的下降趋势完全一致[(6.76±1.99)分,(3.16±1.99)分,( 2.21±1.52)分,F=181.117,P=0.000;(7.13±1.98)分,(3.10±1.79)分,(2.35±1.63)分,F=222.874,P=0.000]。⑤并发症。益气温经方组18例出现一过性胃部不适,基础用药组6例出现一过性胃部不适、4例出现一过性低热。2组并发症发生率比较,差异无统计学意义(χ2=3.145,P=0.076)。结论:口服益气温经方可以降低PMOP肾虚血瘀证患者再骨折的发生率,提高患者骨密度,缓解患者疼痛症状,且安全性高。
Abstract:
Objective:To observe the applied values of Yiqi Wenjing Fang(益气温经方,YQWJF)in treatment of kidney-deficiency-blood-stasis-type postmenopausal osteoporosis(PMOP).Methods:Two hundred and forty patients with kidney-deficiency-blood-stasis-type PMOP were enrolled in the study and were randomly divided into YQWJF group and basic medication group,120 cases in each group.The patients in YQWJF group were treated with oral application of YQWJF(twice a day,200 mL at a time),calcium carbonate and Vitamin D3 tablets(one tablet a day)and alfacalcidol capsules(one capsule a day),while the others in basic medication group were merely with oral application of calcium carbonate and Vitamin D3 tablets and alfacalcidol capsules for consecutive 9 courses of treatment,3 months for each course with a 1-month rest-insertion between courses.The incidence rate of refracture was compared between the 2 groups at the end of treatment and at 2 years after the end of treatment respectively.The bone mineral density(BMD)of lumbar vertebrae and low back pain visual analogue scale(VAS)scores were recorded and compared between the 2 groups before the treatment,at the end of treatment and at 2 years after the end of the treatment respectively,and the complications were observed.Results:Thirteen patients in YQWJF group and seven patients in basic medication group dropped out of the trial for unwillingness to take the requested medications due to diarrhea and taking other medications respectively.At the end of treatment,the refracture was found in 4 patients in YQWJF group and 6 patients in basic medication group.There was no statistical difference in the incidence rate of refracture between the 2 groups(χ2=0.313,P=0.576).At 2 years after the end of treatment,the refracture was found in 6 patients in YQWJF group and 16 patients in basic medication group.The incidence rate of refracture was lower in YQWJF group compared to basic medication group(χ2=4.466,P=0.035).There was interaction between time factor and group factor in BMD of lumbar vertebrae(F=3.063,P=0.048).There was statistical difference in BMD of lumbar vertebrae between the 2 groups in general,in other words,there was group effect(F=11.788,P=0.000).There was statistical difference in BMD of lumbar vertebrae between different timepoints before and after the treatment,in other words,there was time effect(F=4.299,P=0.014).There was no statistical difference in BMD of lumbar vertebrae between pre-treatment and post-treatment in YQWJF group(54.902±32.465,58.174±14.320,54.223±14.053 mg/cm(3),F=0.943,P=0.391); while the BMD of lumbar vertebrae presented a time-dependent decreasing trend in basic medication group(55.449±32.111,50.800±20.377,44.283±10.340 mg/cm(3),F=6.242,P=0.002).There was no statistical difference in BMD of lumbar vertebrae between the 2 groups before the treatment(t=0.126,P=0.900),whereas the BMD of lumbar vertebrae was higher in YQWJF group compared to basic medication group at the end of treatment and at 2 years after the end of treatment(t=3.708,P=0.002; t=5.998,P=0.000)...

参考文献/References:

[1] LANE J M,RUSSELL L,KHAN S N,et al.Osteoporo-sis[J].Clin Orthop Relat Res,2017(372):139-150.
[2] 中华医学会骨质疏松和骨矿盐疾病分会.中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布[J].中华骨质疏松和骨矿盐疾病杂志,2019,12(4):317-318.
[3] 中华中医药学会.绝经后骨质疏松症(骨痿)中医药诊疗指南(2019年版)[J].中医正骨,2020,32(2):1-13.
[4] 黄小生,袁一峰,李少华,等.益气温经法治疗绝经后骨质疏松症的理论探讨[J].中医正骨,2020,32(9):60-62.
[5] 施振宇,刘钟,陈文亮,等.中医综合疗法防治绝经后骨量减少的多中心临床研究[J].中医正骨,2017,29(4):1-7.
[6] 李少华,康石发,孙坚钢,等.强骨饮对肾虚血瘀型绝经后骨质疏松患者跌倒风险因素的影响[J].广州中医药大学学报,2021,38(8):1611-1616.
[7] 中国老年学学会骨质疏松委员会,骨质疏松症诊断标准学科组.中国人骨质疏松症诊断标准专家共识(第三稿·2014版)[J].中国骨质疏松杂志,2014,20(9):1007-1010.
[8] ZENG Q,LI N,WANG Q,et al.The prevalence of osteoporosis in china,a nationwide,multicenter DXA survey[J].J Bone Miner Res,2019,34(10):1789-1797.
[9] MONTELEONE P,MASCAGNI G,GIANNINI A,et al.Symptoms of menopause-global prevalence,physiology and implications[J].Nat Rev Endocrinol,2018,14(4):199-215.
[10] LOKIEC K,BLONSKA A,WALECKA-KAPICA E,et al.Effect of treatment with diet on reducing levels of sex hormones in perimenopausal women with overweight and obesity[J].Pol Merkur Lekarski,2016,40(240):362-368.
[11] SA?DO B,DE HOYO M,DEL POZO-CRUZ J,et al.A systematic review of the exercise effect on bone health:the importance of assessing mechanical loading in perimeno-pausal and postmenopausal women[J].Menopause,2017,24(10):1208-1216.
[12] BLACK D M,ROSEN C J.Clinical Practice.Postmenopausal Osteoporosis[J].N Engl J Med,2016,374(3):254-262.
[13] KANIS J A,COOPER C,RIZZOLI R,et al.European guidance for the diagnosis and management of osteoporosis in postmenopausal women[J].Osteoporos Int,2019,30(1):3-44.
[14] HERNLUND E,SVEDBOM A,IVERG?D M,et al.Osteoporosis in the European Union:medical management,epi-demiology and economic burden.A report prepared in collaboration with the International Osteoporosis Foundation(IOF)and the European Federation of Pharmaceutical Industry Associations(EFPIA)[J].Arch Osteoporos,2013,8(1):136.
[15] 赵凡,刘全,吴连国.口服强骨饮联合碳酸钙D3片治疗绝经后骨质疏松症的临床研究[J].中医正骨,2019,31(4):26-30.
[16] CRANDALL C J,ENSRUD K E.Osteoporosis screening in younger postmenopausal women[J].JAMA,2020,323(4):367-368.
[17] BROWN C.Osteoporosis:staying strong[J].Nature,2017,550(7674):S15-S17.
[18] EASTELL R,O’NEILL T W,HOFBAUER L C,et al.Postmenopausal osteoporosis[J].Nat Rev Dis Primers,2016,2:16069.
[19] ROSSOUW J E,ANDERSON G L,PRENTICE R L,et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results From the Women’s Health Initiative randomized controlled trial[J].JAMA,2002,288(3):321-333.
[20] SHANE E,BURR D,ABRAHAMSEN B,et al.Atypical subtrochanteric and diaphyseal femoral fractures:second report of a task force of the American Society for Bone and Mineral Research[J].J Bone Miner Res,2014,29(1):1-23.
[21] KHOSLA S,BURR D,CAULEY J,et al.Bisphosphonate-associated osteonecrosis of the jaw:report of a task force of the American Society for Bone and Mineral Research[J].J Bone Miner Res,2007,22(10):1479-1491.
[22] KHOSLA S,HOFBAUER L C.Osteoporosis treatment:recent developments and ongoing challenges[J].Lancet Diabetes Endocrinol,2017,5(11):898-907.
[23] 钟如钢,黄小生,袁一峰,等.益气温经方在老年骨质疏松性肱骨近端骨折内固定术后抗骨质疏松治疗中的应用[J].中医正骨,2020,32(6):59-61.
[24] TSENG S H,SUNG C H,CHEN L G,et al.Comparison of chemical compositions and osteoprotective effects of different sections of velvet antler[J].J Ethnopharmacol,2014,151(1):352-360.
[25] WU C F,LIN Y S,LEE S C,et al.Effects of davallia formosana hayata water and alcohol extracts on osteoblastic MC3T3-E1 cells[J].Phytother Res,2017,31(9):1349-1356.
[26] PU X,CHAI Y,GUAN L,et al.Astragalus improve aging bone marrow mesenchymal stem cells(BMSCs)vitality and osteogenesis through VD-FGF23-Klotho axis[J].Int J Clin Exp Pathol,2020,13(4):721-729.
[27] 杨必敬,徐宏光,肖良,等. RhoA/ROCK信号通路介导的细胞形变在人间充质干细胞成骨分化中的调控作用[J].中华医学杂志, 2019,99(3):212-217.
[28] SAIDOVA A A,VOROBJEV I A.Lineage commitment,signaling pathways,and the cytoskeleton systems in mesenchymal stem cells[J].Tissue Eng Part B Rev,2020,26(1):13-25.

相似文献/References:

[1]李林军.应用膨胀式椎弓根螺钉内固定治疗合并骨质疏松的 胸腰椎退行性疾病[J].中医正骨,2015,27(08):49.
[2]李学朋,朱立国.骨疏康胶囊对去卵巢大鼠骨小梁的影响[J].中医正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康胶囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):12.
[3]陈冠军,陈扬,庄汝杰.可灌注骨水泥椎弓根螺钉系统 在老年腰椎疾患手术中的应用[J].中医正骨,2015,27(02):40.
[4]王丹辉,贲越,韩梅.林蛙油治疗绝经后骨质疏松症的临床研究[J].中医正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):27.
[5]黄建华,黄建武,李慧辉,等.加味左归丸对绝经后骨质疏松症肝肾不足证 患者骨密度的影响[J].中医正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(08):19.
[6]项旻,杨虹,林爱菊,等.绝经后2型糖尿病患者骨质疏松与血微量元素的关系研究[J].中医正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(08):20.
[7]史晓林,李春雯,张志强.弱阳离子磁珠分离技术和基质辅助激光解吸电离飞行时间质谱技术在原发性Ⅰ型骨质疏松症血清标志蛋白筛选中的应用[J].中医正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):5.
[8]李明,徐明雄,冯左基,等.自拟壮骨方治疗绝经后骨质疏松症的疗效及作用机制研究[J].中医正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):21.
[9]陈俊杰,李晴晴,夏瑢.脂代谢及血清内脂素水平与绝经后骨质疏松症的 相关性研究[J].中医正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(08):16.
[10]许超,肖鲁伟,吴承亮.绝经后女性骨质疏松症辨证分型与抑郁焦虑的关系研究[J].中医正骨,2011,23(12):3.
　XU Chao*,XIAO Lu-wei,WU Cheng-liang.*.Study on the relationship between the syndrome differ classification and the depression and anxiety for the postmenopausal women with osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(08):3.
[11]韩艳,温利平,刘娜,等.补肾活血方对去卵巢大鼠骨代谢及骨密度的影响[J].中医正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(补肾活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):7.
[12]欧国峰,刘鑫,董博,等.绝经后骨质疏松症的免疫学研究进展[J].中医正骨,2016,28(08):70.
[13]施振宇,刘钟,陈文亮,等.中医综合疗法防治绝经后骨量减少的多中心临床研究[J].中医正骨,2017,29(04):1.
　SHI Zhenyu,LIU Zhong,CHEN Wenliang,et al.A multicenter clinical study of complex therapy of traditional Chinese medicine for prevention and treatment of postmenopausal osteopenia[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(08):1.
[14]梁文娜,李西海,李灿东.血清microRNA与绝经后骨质疏松症肾虚证的关系[J].中医正骨,2017,29(10):53.
[15]梁文娜,李西海,胡柳,等.二至丸抑制绝经后骨质疏松大鼠骨代谢紊乱的作用机制研究[J].中医正骨,2017,29(11):1.
　LIANG Wenna,LI Xihai,HU Liu,et al.Study on mechanism of action of Erzhi Wan(二至丸)in inhibiting bone metabolism disorder in rats with postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(08):1.
[16]刘晨,李兴勇,姚兴璋,等.绝经后骨质疏松症的流行病学概况及发病机制研究进展[J].中医正骨,2018,30(03):52.
[17]杨依然,刘钟,毛一凡,等.酪蛋白激酶-2相互作用蛋白1基于磷脂酰肌醇3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白通路参与绝经后骨质疏松症发生发展过程中细胞自噬的机制[J].中医正骨,2018,30(04):59.
[18]曹俊青,郑剑南,张麟.右归丸联合阿仑膦酸钠口服治疗绝经后骨质疏松症肾阳虚证的临床研究[J].中医正骨,2018,30(05):20.
　CAO Junqing,ZHENG Jiannan,ZHANG Lin.A clinical study of oral application of Yougui Wan(右归丸)and alendronate sodium for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(08):20.
[19]李中万,徐绍俊,杨广钢,等.健肾方联合碳酸钙D3咀嚼片(Ⅱ) 治疗绝经后骨质疏松症肾阳虚证[J].中医正骨,2018,30(08):11.
　LI Zhongwan,XU Shaojun,YANG Guanggang,et al.Oral application of Jianshen Fang(健肾方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(08):11.
[20]赵凡,刘全,吴连国.口服强骨饮联合碳酸钙D3片治疗绝经后骨质疏松症的临床研究[J].中医正骨,2019,31(04):26.
　ZHAO Fan,LIU Quan,WU Lianguo.Oral applications of Qianggu Yin(强骨饮)and calcium carbonate and Vitamin D3 tablets for treatment of postmenopausal osteoporosis:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(08):26.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金项目(81873129,82074183); 浙江省中医药科技计划项目(2018ZZ012,2020ZQ024)
通讯作者:史晓林 E-mail:xlshi-2002@163.com
更新日期/Last Update: 1900-01-01